CoChat
Sign Up
Cited by 276Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well‐characterized cohorts

Open access
Buckley, Rachel F., Mormino, Elizabeth C., Amariglio, Rebecca E., Properzi, Michael J., Rabin, Jennifer S., Lim, Yen Ying, Papp, Kathryn V., Jacobs, Heidi I.L. +20 more·2018·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2018.04.010PMC PMC6131023
Open this paper in CoChat — free account

Abstract

INTRODUCTION: Our objective was to investigate the effect of sex on cognitive decline within the context of amyloid β (Aβ) burden and apolipoprotein E genotype. METHODS: We analyzed sex-specific effects on Aβ-positron emission tomography, apolipoprotein, and rates of change on the Preclinical Alzheimer Cognitive Composite-5 across three cohorts, such as the Alzheimer's Disease Neuroimaging Initiative, Australian Imaging, Biomarker and Lifestyle, and Harvard Aging Brain Study (n = 755; clinical dementia rating = 0; age (standard deviation) = 73.6 (6.5); female = 55%). Mixed-effects models of cognitive change by sex, Aβ-positron emission tomography, and apolipoprotein ε4 were examined with quadratic time effects over a median of 4 years of follow-up. RESULTS: Apolipoprotein ε4 prevalence and Aβ burden did not differ by sex. Sex did not directly influence cognitive decline. Females with higher Aβ exhibited faster decline than males. Post hoc contrasts suggested that females who were Aβ and apolipoprotein ε4 positive declined faster than their male counterparts. DISCUSSION: Although Aβ did not differ by sex, cognitive decline was greater in females with higher Aβ. Our findings suggest that sex may play a modifying role on risk of Alzheimer's disease-related cognitive decline.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2018.04.010

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [1]Mielke MM Vemuri P Rocca WA Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences Clin Epidemiol 2014 6 37 48 24470773 PMC3891487
  2. [3]Chêne G Beiser A Au R Preis SR Wolf PA Dufouil C Gender and incidence of dementia in the Framingham Heart Study from mid-adult life Alzheimer’s & Dementia 2015 11 310 20 PMC4092061 24418058
  3. [4]Fiest KM Roberts JI Maxwell CJ Hogan DB Smith EE Frolkis A The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: a Systematic Review and Meta-Analysis Canadian Journal of Neurological Sciences/Journal Canadien des Sciences Neurologiques 2016 43 S51 S82 27307128
  4. [5]Perera G Pedersen L Ansel D Alexander M Arrighi HM Avillach P Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource Alzheimer’s & Dementia 2018 14 130 9 28734783
  5. [7]Ferreira L Ferreira Santos-Galduróz R Ferri CP Fernandes Galduróz JC Rate of cognitive decline in relation to sex after 60 years-of-age: A systematic review Geriatrics & gerontology international 2014 14 23 31 23682773
  6. [8]Hyman BT Gomez-Isla T Briggs M Chung H Nichols S Kohout F Apolipoprotein E and cognitive change in an elderly population Annals of Neurology 1996 40 55 66 8687193
  7. [9]Mortensen EL Høgh P A gender difference in the association between APOE genotype and age-related cognitive decline Neurology 2001 57 89 95 11445633
  8. [10]Swan GE Lessov-Schlaggar CN Carmelli D Schellenberg GD Rue AL Apolipoprotein E ε4 and Change in Cognitive Functioning in Community-Dwelling Older Adults Journal of Geriatric Psychiatry and Neurology 2005 18 196 201 16306239
  9. [11]McCarrey AC An Y Kitner-Triolo MH Ferrucci L Resnick SM Sex differences in cognitive trajectories in clinically normal older adults Psychology and aging 2016 31 166 26796792 PMC4783196
  10. [13]Jack CR Wiste HJ Weigand SD Knopman DS Mielke MM Vemuri P Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings Brain 2015 PMC4655341 26428666
  11. [14]Lim YY Mormino EC Initiative FtAsDN APOE genotype and early β-amyloid accumulation in older adults without dementia Neurology 2017 89 1028 34 28794245 PMC5589795
  12. [15]Lim YY Ellis KA Ames D Darby D Harrington K Martins RN Aβ amyloid, cognition, and APOE genotype in healthy older adults Alzheimer Dem 2013 9 538 45 23159043
  13. [16]Mormino EC Betensky RA Hedden T Schultz AP Ward A Huijbers W Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease Neurology 2014 82 1760 7 24748674 PMC4035706
  14. [17]Villemagne VL Burnham S Bourgeat P Brown B Ellis KA Salvado O Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989
  15. [18]Sperling RA Rentz DM Johnson KA Karlawish J Donohue M Salmon DP The A4 Study: Stopping AD Before Symptoms Begin? Science Translational Medicine 2014 6 228fs13 PMC4049292 24648338
  16. [19]Aisen PS Petersen RC Donohue MC Gamst A Raman R Thomas RG Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans Alzheimer’s & Dementia 2010 6 239 46 PMC2867843 20451872
  17. [20]Ellis KA Bush A Darby D De Fazio D Foster J Hudson P The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease Int Psychogeriatr 2009 21 672 87 19470201
  18. [21]Dagley A LaPoint M Huijbers W Hedden T McLaren DG Chatwal JP Harvard Aging Brain Study: Dataset and accessibility NeuroImage 2017 144 255 8 25843019 PMC4592689
  19. [22]Papp KV Rentz DM Orlovsky I Sperling RA Mormino EC Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: The PACCC5 Alzheimer’s and Dementia: Translational Research and Clinical Interventions 2017 In press PMC5726754 29264389
  20. [23]Donohue MC Sperling RA Salmon DP Rentz DM Raman R Thomas RG The preclinical alzheimer cognitive composite: Measuring amyloid-related decline JAMA Neurology 2014 71 961 70 24886908 PMC4439182
  21. [24]Burnham SC Bourgeat P Doré V Savage G Brown B Laws S Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study The Lancet Neurology 2016 15 1044 53 27450471
  22. [25]Mormino EC Papp KV Rentz DM Heterogeneity in suspected non–alzheimer disease pathophysiology among clinically normal older individuals JAMA Neurology 2016 73 1185 91 27548655 PMC5266522
  23. [26]Rowe CC Ellis K Rimajova M Bourgeat P Pike KE Jones G Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiology of Aging 2010 31 1275 83 20472326
  24. [27]Landau SM Mintun MA Joshi AD Koeppe RA Petersen RC Aisen PS Amyloid deposition, hypometabolism, and longitudinal cognitive decline Annals of neurology 2012 72 578 86 23109153 PMC3786871
  25. [28]Fischl B Sereno MI Tootell RB Dale AM High-resolution intersubject averaging and a coordinate system for the cortical surface Human brain mapping 1999 8 272 84 10619420 PMC6873338
  26. [29]Donohue MC Sperling RA Petersen R Sun C-K Weiner MW Aisen PS Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons JAMA 2017 317 2305 16 28609533 PMC5736301
  27. [30]Buckley RF Schultz AP Hedden T Papp KV Hanseeuw BJ Marshall G Functional network integrity presages cognitive decline in preclinical Alzheimer disease Neurology 2017 89 29 37 28592457 PMC5496516
  28. [31]Koran MEI Wagener M Hohman TJ Sex differences in the association between AD biomarkers and cognitive decline Brain Imaging and Behavior 2017 11 205 13 26843008 PMC4972701
  29. [32]Van Hooren S Valentijn A Bosma H Ponds R Van Boxtel M Jolles J Cognitive functioning in healthy older adults aged 64–81: a cohort study into the effects of age, sex, and education Aging, Neuropsychology, and Cognition 2007 14 40 54 17164189
  30. [33]Altmann A Tian L Henderson VW Greicius MD Sex modifies the APOE-related risk of developing Alzheimer disease Annals of neurology 2014 75 563 73 24623176 PMC4117990
  31. [35]Jack CR Wiste HJ Weigand SD Knopman DS Vemuri P Mielke MM Age, sex, and APOE ε4 effects on memory, brain structure, and β-amyloid across the adult life span JAMA Neurology 2015 72 511 9 25775353 PMC4428984
  32. [36]Maye JE Betensky RA Gidicsin CM Locascio J Becker JA Pepin L Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring Neurobiology of aging 2016 40 61 7 26973104 PMC4792089
  33. [37]Villeneuve S Vogel JW Gonneaud J Binette AP Rosa-Neto P Gauthier S Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease JAMA neurology 2018 PMC5885216 29482212
  34. [38]Corder EH Ghebremedhin E Taylor MG Thal DR Ohm TG Braak H The Biphasic Relationship between Regional Brain Senile Plaque and Neurofibrillary Tangle Distributions: Modification by Age, Sex, and APOE Polymorphism Annals of the New York Academy of Sciences 2004 1019 24 8 15246987
  35. [41]Hirata-Fukae C Li H-F Hoe H-S Gray AJ Minami SS Hamada K Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model Brain Research 2008 1216 92 103 18486110
  36. [42]Yue X Lu M Lancaster T Cao P Honda S-I Staufenbiel M Brain estrogen deficiency accelerates Aβ plaque formation in an Alzheimer’s disease animal model Proceedings of the National Academy of Sciences of the United States of America 2005 102 19198 203 16365303 PMC1323154
  37. [43]Zheng H Xu H Uljon S Gross R Hardy K Gaynor J Modulation of Aβ peptides by estrogen in mouse models Journal of neurochemistry 2002 80 191 6 11796757
  38. [44]Huang J Guan H Booze RM Eckman CB Hersh LB Estrogen regulates neprilysin activity in rat brain Neuroscience Letters 2004 367 85 7 15308303
  39. [45]Rentz DM Weiss BK Jacobs EG Cherkerzian S Klibanski A Remington A Sex differences in episodic memory in early midlife: Impact of reproductive aging Menopause 2017 24 400 8 27824681 PMC5365356
  40. [46]Rocca WA Bower JH Maraganore DM Ahlskog JE Grossardt BR de Andrade M Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause Neurology 2007 69 1074 83 17761551
  41. [47]Shao H Breitner JCS Whitmer RA Wang J Hayden K Wengreen H Hormone therapy and Alzheimer disease dementia: New findings from the Cache County Study Neurology 2012 79 1846 52 23100399 PMC3525314
  42. [48]Henderson VW Alzheimer’s disease: Review of hormone therapy trials and implications for treatment and prevention after menopause The Journal of Steroid Biochemistry and Molecular Biology 2014 142 99 106 23727128 PMC3830600
  43. [49]Damoiseaux JS Seeley WW Zhou J Shirer WR Coppola G Karydas A Gender Modulates the APOE ε4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels The Journal of Neuroscience 2012 32 8254 62 22699906 PMC3394933
  44. [50]Sampedro F Vilaplana E De Leon MJ Alcolea D Pegueroles J Montal V APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls Oncotarget 2015 6 26663 26397226 PMC4694943
  45. [53]Domingue BW Belsky DW Harrati A Conley D Weir DR Boardman JD Mortality selection in a genetic sample and implications for association studies International Journal of Epidemiology 2017 46 1285 94 28402496 PMC5837559
  46. [54]Blacker D Haines JL Rodes L Terwedow H Go RCP Harrell LE ApoE-4 and Age at Onset of Alzheimer’s Disease: The NIMH Genetics Initiative Neurology 1997 48 139 47 9008509
  47. [55]Mozaffarian D Benjamin EJ Go AS Arnett DK Blaha MJ Cushman M Heart disease and stroke statistics—2016 update Circulation 2016 133 e38 e360 26673558
  48. [56]Jansen WJ Ossenkoppele R Tijms BM Fagan AM Hansson O Klunk WE Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia JAMA psychiatry 2018 75 84 95 29188296 PMC5786156
  49. [57]Gross AL Sherva R Mukherjee S Newhouse S Kauwe JSK Munsie LM Calibrating Longitudinal Cognition in Alzheimer’s Disease Across Diverse Test Batteries and Datasets Neuroepidemiology 2014 43 194 205 25402421 PMC4297570
  50. [58]Gross AL Hassenstab JJ Johnson SC Clark LR Resnick SM Kitner-Triolo M A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2017 8 147 55 PMC5476965 28653035

Cited by

Sorted by citations

Authors
Buckley, R. F., Mormino, E. C., Amariglio, R. E., Properzi, M. J., Rabin, J. S., Lim, Y. Y., Papp, K. V., Jacobs, H. I. L., Burnham, S., Hanseeuw, B. J., Doré, V., Dobson, A., Masters, C. L., Waller, M., Rowe, C. C., Maruff, P., Donohue, M. C., Rentz, D. M., Kirn, D., Hedden, T., Chhatwal, J., Schultz, A. P., Johnson, K. A., Villemagne, V. L., Sperling, R. A., Initiative, O. B. O. C. I. T. A. D. N., the Australian Imaging, B. A. L. S. O. A., & Study, T. H. A. B.
Affiliations
  • Brigham and Women's Hospital (US)
  • Stanford Medicine (US)
  • Harvard University (US)
  • The University of Melbourne (AU)
  • Commonwealth Scientific and Industrial Research Organisation (AU)
  • The University of Queensland (AU)
  • Cogstate, Ltd. Australia
  • University of Southern California (US)
  • Alzheimer’s Disease Neuroimaging Initiative (US)
Corresponding author
Buckley, Rachel F.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2018-05-24
Volume
14
Issue
9
Pages
1193-1203
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2018.04.010
PMC
PMC6131023
OpenAlex
W2803902280
Cited by
276
References
8
Citations by year
2026: 36 · 2025: 40 · 2024: 24 · 2023: 35 · 2022: 37 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 5
FWCI
20.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
Funders
  • Alzheimer Nederland (WE.15-2014-06)
  • National Institutes of Health (K01 040197, P01 AG036694, P50 AG005134, K23 EB019023, K23 AG049087, K24 AG035007, R01EB014894, R21 AG038994, R01 AG026484, R01 AG034556, P50 AG00513421, U19 AG10483, R13 AG042201174210, R01 AG027435, R01 AG037497)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • U.S. Department of Defense (W81XWH-12-2-0012)
  • Alzheimer's Association (ZEN-10-174210)
  • Eli Lilly and Company (P01 AG036694, U01 AG032438, U01 AG024904, R01 AG037497, R01 AG034556, K24 AG035007, P50 AG005134, U19 AG010483, R01 AG027435)
  • Fidelity Biosciences
  • Harvard NeuroDiscovery Center
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
sex differences, amyloid-beta
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Risk Factors, Sex Factors, Cohort Studies, Amyloid beta-Peptides, Disease Progression, Apolipoprotein E4, Cognitive Dysfunction, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review